Search Results

You searched for : LatestBristolMyersSquibbNews

	Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo Plus Yervoy Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma ... Jul 17
	Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy Recommendation based on positive results from the Phase 3 CheckMate -577 trial in which Opdivo doubled disease-free survival compared to placebo in the all-... Jun 25
	European Medicines Agency Validates Bristol Myers Squibbâ€™s Application for Opdivo ... Jan 05
	European Medicines Agency Validates Bristol Myers Squibbâ€™s Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis If approved, Zeposia would be the first oral sphingosine-1-phosphate (S1P) receptor modulator for the treatment of ulcerative colitis.... Dec 28
	Bristol Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed Methylated Glioblastoma Multiforme ... Dec 23
	Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic for Adult Patients with Myelofibrosis If approved, Inrebic will become the first new therapy for myelofibrosis in Europe in nearly a decade.... Dec 11
	Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR AML-001 Study of Onureg Results demonstrated treatment with Onureg improved overall survival, compared to placebo, in patients with AML in first remission.... Dec 08
	Bristol Myers Squibb Receives European Commission Approval for Opdivo Bristol Myers Squibb announced the approval of Opdivo for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma ... Nov 25
	Decreases in Americans' Primary Care Visits May Lead to Late Diagnoses of Potentially Serious Conditions The Bristol Myers Squibbâ€“Pfizer Alliance, with the support of leading advocacy organizations and medical societies, announces the launch of the No Time to Wait ... Oct 26
	USFDA Accepts for Priority Review Applications for OPDIVO in Combination with CABOMETYX in Advanced Renal Cell Carcinoma Results from CheckMate -9ER recently presented during a Presidential Symposium at the European Society for Medical Oncology Virtual Congress... Oct 19
10 Matching result(s) found!

-Advertisements-

Trending Now
	Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
	International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
	The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
	Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
	Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
	In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
	Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
	Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
	10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
	Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
	The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
	Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
	A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
	The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
	ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
	The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
	Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
	Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
	AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
	Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024

Search Results

Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo Plus Yervoy Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy

European Medicines Agency Validates Bristol Myers Squibbâ€™s Application for Opdivo

European Medicines Agency Validates Bristol Myers Squibbâ€™s Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis

Bristol Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed Methylated Glioblastoma Multiforme

Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic for Adult Patients with Myelofibrosis

Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR AML-001 Study of Onureg

Bristol Myers Squibb Receives European Commission Approval for Opdivo

Decreases in Americans' Primary Care Visits May Lead to Late Diagnoses of Potentially Serious Conditions

USFDA Accepts for Priority Review Applications for OPDIVO in Combination with CABOMETYX in Advanced Renal Cell Carcinoma

Trending Now